Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.03 | N/A | +149.26% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.03 | N/A | +149.26% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings performance despite not providing specific revenue figures. They emphasized their commitment to advancing their pipeline.
The company is pleased with the positive EPS surprise.
Management highlighted ongoing efforts in product development.
PTC Therapeutics reported a positive earnings surprise, with EPS significantly exceeding expectations. The stock reacted positively, rising by 0.68%. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DAVE INC A
Mar 5, 2018